We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals, Inc.
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

Back to rankings

1 hedge funds and large institutions have $76K invested in Dicerna Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more capital invested

Capital invested by funds: $76K → $76K ($0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Close Asset Management
United Kingdom
$76K – – –

DRNA Hedge Fund Activity: Q1 2022 in Review

1 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2022, worth a combined $76K — unchanged from a quarter earlier.

Fund positioning in DRNA was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $76K of Dicerna Pharmaceuticals, Inc. stock for Q1 2022, unchanged quarter-over-quarter.
  • 0 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2022 and 0 closed out.

Based on aggregated 13F filings for Q1 2022.